1. Home
  2. GTIM vs CMMB Comparison

GTIM vs CMMB Comparison

Compare GTIM & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Good Times Restaurants Inc.

GTIM

Good Times Restaurants Inc.

HOLD

Current Price

$1.25

Market Cap

13.6M

ML Signal

HOLD

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

HOLD

Current Price

$2.48

Market Cap

13.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GTIM
CMMB
Founded
1987
2004
Country
United States
Israel
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.6M
13.8M
IPO Year
1990
N/A

Fundamental Metrics

Financial Performance
Metric
GTIM
CMMB
Price
$1.25
$2.48
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$26.50
AVG Volume (30 Days)
53.1K
84.4K
Earning Date
12-11-2025
11-20-2025
Dividend Yield
N/A
N/A
EPS Growth
17.03
N/A
EPS
0.12
N/A
Revenue
$143,398,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.60
N/A
Revenue Growth
1.78
N/A
52 Week Low
$1.17
$2.36
52 Week High
$2.90
$9.84

Technical Indicators

Market Signals
Indicator
GTIM
CMMB
Relative Strength Index (RSI) 38.50 41.76
Support Level $1.23 $2.42
Resistance Level $1.33 $2.68
Average True Range (ATR) 0.07 0.19
MACD 0.01 0.01
Stochastic Oscillator 47.09 24.53

Price Performance

Historical Comparison
GTIM
CMMB

About GTIM Good Times Restaurants Inc.

Good Times Restaurants Inc is engaged in developing, owning, operating, and franchising hamburger-oriented drive-through restaurants. It operates through two segments: Good Times Burgers and Frozen Custard restaurants which operate in the quick-service drive-through dining industry; and Bad Daddy's Burger Bar restaurants which operate in the full-service upscale casual dining industry. The company generates maximum revenue from the Bad Daddy's Burger Bar restaurants segment. Its menu categories include burgers; chicken; frozen custard; slides and drinks.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Share on Social Networks: